Statins induce lethal effects in acute myeloblastic leukemia cells within 72 hours

References

• Dale K M, Coleman C I, Henyan N N, Kluger J, White C M. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74–80
   PubMed Web of Science ®Google Scholar
• Poynter J N, Gruber S B, Higgins P D, Almog R, Bonner J D, Rennert H S, et al. HMG CoA reductase inhibitors and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184–2192
   PubMed Web of Science ®Google Scholar
• Chan K KW, Oza A M, Siu L L. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10–19
   PubMed Web of Science ®Google Scholar
• Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A, et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000; 14: 1444–1450
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Nohynek D, Backway K L, Hedley D W, Yeger H, Freedman M H, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999; 93: 1308–1318
   PubMed Web of Science ®Google Scholar
• Hunakova L, Sedlak J, Sulikova M, Chovancova J, Duraj J, Chorvath B. Human multidrug-resistant myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin. Neoplasia 1997; 44: 366–369
   Google Scholar
• Diamond A M, Jaffe D, Murray J L, Safa A R, Samuels B L, Hatfield D L, et al. Lovastatin effects on human breast carcinoma cells. Differential toxicity of an adriamycin-resistant derivative and influence on selenocysteine tRNAS. Biochem Mol Biol Int 1996; 38: 345–355
   PubMedGoogle Scholar
• Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43: 1221–1228
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 1996; 2: 326–333
   PubMed Web of Science ®Google Scholar
• Grundy S M, Cleeman J I, Merz C N, Brewer H B, Jr, Clark L T, Hunninghake D B, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720–732
   PubMed Web of Science ®Google Scholar
• Wong W W, Dimitroulakos J, Minden M D, Penn L Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508–519
   PubMed Web of Science ®Google Scholar
• Xia Z, Tan M M, Wong W W, Dimitroulakos J, Minden M D, Penn L Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15: 1398–1407
   PubMed Web of Science ®Google Scholar
• Stirewalt D L, Appelbaum F R, Willman C L, Zager R A, Banker D E. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 2003; 27: 133–145
   PubMed Web of Science ®Google Scholar
• Scheffold C, Schottker B, Lefterova P, Csipai M, Glasmacher A, Huhn D, et al. Increased sensitivity of myeloid leukemia cell lines: potential of lovastatin as bone-marrow-purging agent. Acta Haematol 2000; 104: 72–79
   PubMed Web of Science ®Google Scholar
• Walsh K M, Albassam M A, Clarke D E. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol 1996; 24: 468–476
   PubMed Web of Science ®Google Scholar
• Holstein S A, Knapp H R, Clamon G H, Murry D J, Hohl R J. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006; 57: 155–164
   PubMed Web of Science ®Google Scholar
• Walsh K M, Rothwell C E. Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Toxicol Pathol 1999; 27: 395–401
   PubMed Web of Science ®Google Scholar
• Thibault A, Samid D, Tompkins A C, Figg W D, Cooper M R, Hohl R J, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483–491
   PubMed Web of Science ®Google Scholar
• Knox J J, Siu L L, Chen E, Dimitroulakos J, Kamel-Reid S, Moore M J, et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005; 41: 523–530
   PubMed Web of Science ®Google Scholar
• Hancock J F. Prenylation and palmitoylation analysis. Methods Enzymol 1995; 255: 237–245
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Thai S, Wasfy G H, Hedley D W, Minden M D, Penn L Z. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000; 40: 167–178
   PubMed Web of Science ®Google Scholar
• Maltese W A, Sheridan K M, Repko E M, Erdman R A. Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid. J Biol Chem 1990; 265: 2148–2155
   PubMed Web of Science ®Google Scholar
• Clutterbuck R D, Millar B C, Powles R L, Newman A, Catovsky D, Jarman M, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 1998; 102: 522–557
   PubMed Web of Science ®Google Scholar
• Li H Y, Appelbaum F R, Willman C L, Zager R A, Banker D E. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628–3634
   PubMed Web of Science ®Google Scholar
• van der Spek E, Bloem A C, van de Donk N W, Bogers L H, van der Griend R, Kramer M H, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006; 91: 542–545
   PubMed Web of Science ®Google Scholar
• Zhong W B, Wang C Y, Chang T C, Lee W S. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003; 144: 3852–3859
   PubMed Web of Science ®Google Scholar
• Holmberg M, Sandberg C, Nygren P, Larsson R. Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs 1994; 5: 598–600
   PubMed Web of Science ®Google Scholar
• Kornblau S M, Banker D E, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007; 109: 2999–3006
   PubMed Web of Science ®Google Scholar
• Holstein S A, Hohl R J. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 2001; 25: 651–660
   PubMed Web of Science ®Google Scholar
• Lishner M, Bar-Sef A, Elis A, Fabian I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 2001; 49: 319–324
   PubMed Web of Science ®Google Scholar